CStone Pharmaceuticals, a China-based biopharmaceutical company, has entered into an exclusive commercialisation agreement with Arrotex Pharmaceuticals, a core pharmaceutical commercialisation platform of DBG Health, Australia's largest diversified healthcare group, for the commercialisation of sugemalimab in Australia and New Zealand.
Under the terms of the agreement, CStone will receive an upfront payment from Arrotex and is eligible for additional regulatory and commercial milestone payments. CStone will supply sugemalimab to Arrotex and recognize a profit share arrangement.
Arrotex will hold exclusive commercialisation rights for sugemalimab in Australia and New Zealand across all approved and future indications, including stage III and IV non-small cell lung cancer (NSCLC), gastric cancer (GC), esophageal squamous cell carcinoma (ESCC), and extranodal NK/T-cell lymphoma (ENKTL), subject to regulatory approval by Australia's Therapeutic Goods Administration (TGA).
Arrotex will be responsible for regulatory submissions and commercialisation activities in the licensed territory.
The anti-PD-L1 monoclonal antibody sugemalimab has been developed by CStone using OmniRat® transgenic animal platform, which allows creation of fully human antibodies in one step.
